US equities look set to open slightly higher in Friday's trading session with tech stocks rebounding modestly following a week-long rout, as stocks such as NVIDIA (NVDA), Microsoft (MSFT), and Tesla (TSLA) rise pre-bell.

The Dow Jones Industrial Average futures were up 0.5%, S&P 500 futures were rising 0.5%, and Nasdaq futures were 0.6% higher.

Oil prices were falling, with front-month global benchmark North Sea Brent crude down 0.6% to $67.15 per barrel, while US West Texas Intermediate crude was 0.7% lower at $62.84 per barrel.

In other world markets, Japan's Nikkei rose 0.8%, Hong Kong's Hang Seng fell 1.2%, and China's Shanghai Composite was off 0.3%. Meanwhile, in Europe's early afternoon session, the UK's FTSE 100 was edging 0.2% higher, while Germany's DAX rose 0.5% and France's CAC was little changed.

In equities, shares of Encompass Health (EHC) surged 17% after it reported rising Q4 adjusted earnings and revenue late Thursday that surpassed analysts' expectations, according to analysts surveyed by FactSet.

Roivant Sciences' (ROIV) stock surged 15% after its Priovant Therapeutics unit said Friday that the phase 2 study of its experimental drug brepocitinib showed improvement in cutaneous sarcoidosis disease activity at higher doses.

Shares of Bloom Energy (BE) advanced 14% after it reported higher Q4 adjusted earnings and revenue late Thursday, as well as 2026 guidance that beat Street forecasts, according to analysts surveyed by FactSet.

On the losing side, shares of Molina Healthcare (MOH) plunged 32% after it reported a Q4 adjusted loss late Thursday of $2.75 per diluted share, swinging from earnings of $5.05 a year earlier, and missing analyst expectations of a $0.34 profit, according to FactSet. The company also provided 2026 guidance that fell short of analyst forecasts.

Stellantis (STLA) shares tumbled 24% after it said Friday that it will take a 22.2 billion-euro ($26.2 billion) charge, citing significantly reduced expectations for battery electric vehicle products.

Impinj's (PI) stock dropped about 25% after Evercore ISI analysts downgraded the company's stock rating to in line from outperform, and slashed its price target to $112 From $273.